SCHEMBL3333336

SCHEMBL3333336

CCOc1nc(N)nc2ccc(-c3ccsc3)cc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH1 P35367 1/20 0.46
HRH4 Q9H3N8 1/20 0.46
HRH3 Q9Y5N1 1/20 0.46
BACE1 P56817 1/20 0.46
GAK O14976 1/20 0.42
PDE3A Q14432 1/20 0.42
CCNE2 O96020 1/20 0.41
CDK4 P11802 1/20 0.41
CCND1 P24385 1/20 0.41
CCNE1 P24864 1/20 0.41
CDK2 P24941 1/20 0.41
CHEK2 O96017 1/20 0.40
KCNH2 Q12809 1/20 0.40
PDGFRB P09619 5/20 0.39
PDGFRA P16234 5/20 0.39
DHFR P00374 1/20 0.39
AAK1 Q2M2I8 1/20 0.39
MAP4K4 O95819 1/20 0.38
ADORA2A P29274 1/20 0.37
ADORA1 P30542 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3337803 0.87 HRH1 (0.44) HRH1HRH4HRH3BACE1GAK
SCHEMBL3331148 0.83 DHFR (0.48) CCNE2CCNE1CDK2DHFRAAK1
SCHEMBL3338558 0.82 HRH1 (0.46) HRH1HRH4HRH3BACE1GAK
SCHEMBL3334236 0.82 HSP90AB1 (0.50) DHFRAAK1MAP4K4ADORA2AMEN1
SCHEMBL3336357 0.82 TRIM58 (0.43) HRH1HRH4HRH3BACE1CDK2
SCHEMBL3337583 0.81 MAP4K4 (0.47) DHFRAAK1MAP4K4ADORA2APIK3CD
SCHEMBL3336519 0.81 ESR1 (0.41) CCNE2CDK4CCND1CCNE1CDK2
SCHEMBL3340999 0.80 DHFR (0.40) PDGFRBPDGFRADHFRAAK1MAP4K4
SCHEMBL3336195 0.79 ADORA2A (0.45) CCNE2CDK4CCND1CCNE1CDK2
SCHEMBL3337794 0.79 DHFR (0.48) PDGFRBPDGFRADHFRADORA1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8673929-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections GILEAD SCIENCES, INC. (US) 2014-03-18 US claimed
US-20100143299-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2010-06-10 US claimed
WO-2008009077-A2 4,6-DL- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2008-01-24 WO claimed
US-8673929-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections GILEAD SCIENCES, INC. (US) 2014-03-18 US disclosed
US-20100143299-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2010-06-10 US disclosed
WO-2008009077-A2 4,6-DL- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2008-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100143299-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS OPRD1, IFNAR1, NR4A1 HRH1 124/4885HRH4 18/4885HRH3 96/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.